Conceptos Categóricos

Crónicas de autores

Carmen Rodriguez-Avial *

Autora invitada por SIIC

Ejemplo preocupante de la imposibilidad de erradicar una infección y sus consecuencias.

KLEBSIELLA PNEUMONIAE, PRODUCTORA DE (BLEE), PRESENTA “IN VIVO” RESISTENCIA A IMIPENEM Y TIGECICLINA.

Desarrollo in vivo de resistencia a imipenem, por producción de VIM-1, y a tigeciclina, en Klebsiella pneumoniae, productora de BLEE, durante el tratamiento prolongado con diferentes antimicrobianos de una urosepsis en un paciente receptor de trasplante renal. Es un ejemplo preocupante de la imposibilidad de erradicar una infección y de sus consecuencias.

*Carmen Rodriguez-Avial
describe para SIIC los aspectos relevantes de su trabajo
KLEBSIELLA PNEUMONIAE: DEVELOPMENT OF A MIXED POPULATION OF CARBAPENEM AND TIGECYCLINE RESISTANCE DURING ANTIMICROBIAL THERAPY IN A KIDNEY TRANSPLANT PATIENT
Clinical Microbiology and Infection,
18(1):61-66 Ene, 2012

Esta revista, clasificada por SIIC Data Bases, integra el acervo bibliográfico
de la Biblioteca Biomédica (BB) SIIC.

Institución principal de la investigación
*Universidad Complutense de Madrid, Madrid, España
Imprimir nota
Referencias bibliográficas
1. Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 20:440-458, 2007.
2. Walsh TR, Toleman MA, Poirel L, et al. Metallo-beta-lactamases: the quiet before the storm? Clin Microbiol Rev 18:306-325, 2005.
3. Deshpande LM, Jones RN, Fritsche TR, et al. Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004). Microb Drug Resist 12:223-230, 2006.
4. Pournaras S, Ikonomidis A, Tzouvelekis LS, et al. VIM-12, a novel plasmid-mediated metallo-beta-lactamase from Klebsiella pneumoniae that resembles a VIM-1/VIM-2 hybrid. Antimicrob Agents Chemother 49:5153-5156, 2005.
5. Giakkoupi P, Xanthaki A, Kanelopoulou M, et al. VIM-1 Metallo-betalactamase-producing Klebsiella pneumoniae strains in Greek hospitals. J Clin Microbiol 41:3893-3896, 2003.
6. Aschbacher R, Doumith M, Livermore DM, et al. Linkage of acquired quinolone resistance (qnrS1) and metallo-beta-lactamase (blaVIM-1) genes in multiple species of Enterobacteriaceae from Bolzano, Italy. J Antimicrob Chemother 61:515-523, 2008.
7. Weile J, Ohler S, Schonthal S, et al. A VIM-1 metallo-beta-lactamase-producing-Klebsiella pneumoniae clinical isolate in an acute hospital in Germany. Int J Antimicrob Agents 33:389-391, 2009.
8. Tortola MT, Lavilla S, Miro E, et al. First detection of a carbapenem-hydrolyzing metalloenzyme in two Enterobacteriaceae isolates in Spain. Antimicrob Agents Chemother 49:3492-3494, 2005.
9. Tato M, Coque TM, Ruiz-Garbajosa P, et al. Complex clonal and plasmid epidemiology in the first outbreak of Enterobacteriaceae infection involving VIM-1 metallo-beta-lactamase in Spain: toward endemicity? Clin Infect Dis 45:1171-1178, 2007.
10. Psichogiou M, Tassios PT, Avlamis A, et al. Ongoing epidemic of bla-VIM-1-positive Klebsiella pneumoniae in Athens, Greece: a prospective survey. J Antimicrob Chemother 61:59-63, 2008.
11. Kassis-Chikhani N, Decre D, Gautier V et al. First outbreak of multidrug-resistant Klebsiella pneumoniae carrying blaVIM-1 and blaSHV-5 in a French university hospital. J Antimicrob Chemother 57:142-145, 2006.
12. Ktari S, Arlet G, Mnif B, et al. Emergence of multidrug-resistant Klebsiella pneumoniae isolates producing VIM-4 metallo-beta-lactamase, CTX-M-15 extended-spectrum beta-lactamase, and CMY-4 AmpC beta-lactamase in a Tunisian university hospital. Antimicrob Agents Chemother 50:4198-4201, 2006.
13. Galani I, Rekatsina PD, Hatzaki D, et al. Evaluation of different laboratory tests for the detection of metallo-beta-lactamase production in Enterobacteriaceae. J Antimicrob Chemother 61:548-553, 2008.
14. Picao RC, Andrade SS, Nicoletti AG, et al. Metallo-beta-lactamase detection: comparative evaluation of double-disk synergy versus combined disk tests for IMP-, GIM-, SIM-, SPM-, or VIM-producing isolates. J Clin Microbiol 46:2028-2037, 2008.
15. Castanheira M, Sader H, Deshpande, L et al. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and Metallo-beta-lactamase-producing Enterobacteriaceae. Report from the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother 52:570-573, 2008.
16. Conejo MC, Hernandez JR, Pascual A. Effect of porin loss on the activity of tigecycline against Klebsiella pneumoniae producing extended-spectrum beta-lactamases or plasmid-mediated AmpC-type beta-lactamases. Diagn Microbiol Infect Dis 61:343-345, 2008.
17. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 19th Informational Supplement. CLSI Document M100-S19. Wayne, PA: CLSI, 2009.
18. Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative
aerobes. Clin Microbiol Infect 8:321-331, 2002.
19. Coque TM, Oliver A, Pérez-Díaz JC, et al. Genes encoding TEM-4, SHV-2, and CTX-M-10 extended-spectrum beta-lactamases are carried by multiple Klebsiella pneumoniae clones in a single hospital (Madrid, 1989 to 2000). Antimicrob Agents Chemother 46:500-510, 2002.
20. Tenover FC, Arbeit RD, Goering RV et al. Interpreting chromosomal DNA restriction patterns produced by pulsed- field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 33:2233-2239, 1995.
21. Gulmez D, Woodford N, Palepou MF et al. Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates from Turkey with OXA-48-like carbapenemases and outer membrane protein loss. Int J Antimicrob Agents 31:523-526, 2008.
22. Hong T, Smith Moland E, Abdalhamid B et al. Escherichia coli: development of carbapenem resistance during therapy. Clin Infect Dis 40:84-86, 2005.
23. Giakkoupi P, Tzouvelekis LS, Daikos GL et al. Discrepancies and interpretation problems in susceptibility testing of VIM-1-producing Klebsiella pneumoniae isolates. J Clin Microbiol 43:494-496, 2005.
24. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 20th Informational Supplement. CLSI Document M100-S20. Wayne, PA: CLSI, 2010.
25. Cobo J, Morosini MI, Pintado V et al. Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 beta-lactamase-producing Klebsiella pneumoniae epidemic clone. Diagn Microbiol Infect Dis 60:319-322, 2008.
26. Daly MW, Riddle DJ, Ledeboer NA et al. Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae. Pharmacotherapy 27:1052-1057, 2007.
27. Anthony KB, Fishman NO, Linkin DR et al. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 2008; 46:567-570, 2008.
28. Kelesidis T, Karageorgopoulos DE, Kelesidis I et al. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 62:895-904, 2008.
29. Keeney D, Ruzin A, Bradford PA. RamA, a transcriptional regulator, and AcrAB, an RND-type efflux pump, are associated with decreased susceptibility to tigecycline in Enterobacter cloacae. Microb Drug Resist 13:1-6, 2007.
30. Rasheed JK, Jay C, Metchock B et al. Evolution of extended-spectrum beta-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia. Antimicrob Agents Chemother 41:647-653, 1997.
31. Fishman JA. Infection in renal trasplant recipients. Semin Nephrol 27:445-461, 2007.
Otros artículos de Carmen Rodriguez-Avial

Rodríguez-Avial I, Rodríguez-Avial C, Culebras E, Benítez A, Picazo JJ. Distribution of mef(A) and erm(B) genes in macrolide-resistant blood isolates of viridans group streptococci. J Antimicrob Chemotherapy 47:719-730, 2001.
González-Praetorius A, Rodríguez-Avial C, Fernández C, Pérez-Pomata MT, Gimeno C, Bisquert J. Prevalencia de hepatitis A en la provincia de Guadalajara. ¿Es España un país de baja endemia? Enferm Infecc Microbiol Clin 19:428-431, 2001.
Rodríguez-Avial C, Rodríguez-Avial I, Picazo JJ. Sensibilidad a penicilina y otros 13 antimicrobianos de estreptococo del grupo viridans resistentes a eritromicina aislados de hemocultivos. Rev Esp Quimioterap 14(3):275-280, 2001.
Rodríguez-Avial I, Rodríguez-Avial C, Picazo JJ. Actividad in vitro de seis fluoroquinolonas y penicilina frente a 101 estreptococos del grupo viridans caracterizados en su resistencia a la eritromicina. Rev Esp Quimioterap 14(4):364-368, 2001.
Rodríguez-Avial I, Rodríguez-Avial C, Culebras E, Picazo JJ. Distribution of tetracycline resistance genes tet(M), tet(O), tet(L) and tet(K) in blood isolates of viridans group streptococci harbouring mef(A) and erm(B) genes. Susceptibility to quinupristin/dalfopristin and linezolid. Int J Antimicrob Agents 21:536-541, 2003.
Rodríguez-Avial I, Rodríguez-Avial C, Culebras E, Picazo JJ. In vitro activity of Telithromycin against viridans group streptococci and Streptococcus bovis isolated from blood: Antimicrobial susceptibility patterns in different group of species. Antimicrob Agents Chemother 49:820-823, 2005.
Rodriguez-Avial I, Rodríguez-Avial C, López O, Picazo JJ. Trends in nalidixico acid resistance in nontyphoidal Salmonella isolated from 1999 to 2002: decreased susceptibility to 6 fluoroquinolones. Diagnostic Microbiology and Infectious Diseases 52:261-264, 2005.
Rodríguez-Avial I, Rodríguez-Avial C, López O, Culebras E, Picazo JJ. In vitro activity of tigecycline (GAR-936) and other antimicrobials against tetracycline-and ciprofloxacin resistant Campylobacter clinical isolates. International Journal of Antimicrobial Agents 27:303-306, 2006.
Ríos E, Rodríguez-Avial I, Rodríguez-Avial C, Hernández E, Picazo JJ. High percentage of resistance to ciprofloxacin and qnrB19 gene identified in urinary isolates of extended-spectrum betalactamase-producing Escherichia coli in Madrid, Spain. Diagnostic Microbiology and Infectious Diseases 67:380-383, 2010.

Para comunicarse con Carmen Rodriguez-Avial mencionar a SIIC como referencia:
cravial@med.ucm.es

Autora invitada
24 de enero, 2012
Descripción aprobada
13 de abril, 2012
Reedición siicsalud
31 de agosto, 2021

Acerca del trabajo completo
KLEBSIELLA PNEUMONIAE, PRODUCTORA DE (BLEE), PRESENTA “IN VIVO” RESISTENCIA A IMIPENEM Y TIGECICLINA.

Título original en castellano
KLEBSIELLA PNEUMONIAE: DESARROLLO DE UNA POBLACION MIXTA, RESISTENTE A CARBAPENEMICOS Y TIGECICLINA, EN UN PACIENTE TRANSPLANTADO DE RIÑON , A LO LARGO DE SU TRATAMIENTO CON ANTIMICROBIANOS.

Autor


Acceso a la fuente original
Clinical Microbiology and Infection
http://www.blackwellpublishing.com/journal.asp?ref=1198-743X&site=1

El artículo se relaciona estrictamente con las especialidades de siicsalud


ua40317
-->